香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Gaush Meditech Ltd 高視醫療科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） （股 份 代 號：2407） 建議修訂現有組織章程大綱及 細則並採納新組織章程大綱及細則 本公告由高視醫療科技有限公司（「本公司」）根據香港聯合交易所有限公司證 券上市規則（「上市規則」）第13.51(1)條作出，內容有關建議修訂本公司第六次 經修訂及重列組織章程大綱及細則（「現有組織章程大綱及細則」）。 主席兼執行董事 高鐵塔先生 香港，2026年3月26日 於本公告日期，董事會包括主席兼執行董事高鐵塔先生，執行董事劉新偉先生、趙新禮先生、 張建軍先生及李文奇女士，非執行董事David Guowei Wang博士，以及獨立非執行董事馮昕先 生、王立新先生及陳帆城先生。 – 2 – 本公司董事（「董事」）會（「董事會」）建議對現有組織章程大綱及細則作出修訂， 以符合上市規則 ...

Financial Performance - For the fiscal year ending December 31, 2025, the company's revenue was RMB 1,380.4 million, a decrease of 3.4% compared to RMB 1,428.4 million for the fiscal year ending December 31, 2024[2][8]. - The net profit for the fiscal year ending December 31, 2025, was RMB 91.2 million, an increase of 3.1% from RMB 88.5 million in the previous year[2][5]. - Basic earnings per share for the fiscal year ending December 31, 2025, were RMB 0.66, up from RMB 0.63 for the fiscal year ending December 31, 2024[2]. - The gross profit decreased by 4.6% from RMB 663.4 million for the year ending December 31, 2024, to RMB 633.2 million for the year ending December 31, 2025, with the gross margin declining from 46.4% to 45.9%[32]. - The group recorded a foreign exchange gain of RMB 82.0 million for the year ended December 31, 2025, compared to a loss of RMB 36.6 million for the previous year[55]. - The total tax expense for the year was RMB 23,493,000, significantly lower than RMB 66,764,000 in 2024, reflecting a reduction of 64.8%[111]. - The net profit attributable to shareholders for the year was RMB 96,189, compared to RMB 92,394 in 2024, representing an increase of 4.3%[73]. Research and Development - Research and development expenses for the fiscal year ending December 31, 2025, were RMB 92.6 million, an increase of 18.1% from RMB 78.4 million in the previous year, representing 6.7% of revenue[2][5]. - The company has expanded its R&D capabilities with platforms in Shenzhen, Wuxi, Suzhou, and Wenzhou in China, as well as in the Netherlands and Germany[6]. - The company’s R&D investments focus on artificial crystals, surgical consumables, and diagnostic equipment, with significant progress in product registration expected in 2026[19]. - The company’s Shenzhen base has made advancements in developing various ophthalmic products, with several products entering clinical trials and registration processes[17]. - The company has a global R&D layout with 257 personnel, accounting for approximately 28.8% of total employees, and R&D expenses of RMB 92.6 million, representing 21.6% of proprietary product revenue, an 18.1% increase from RMB 78.4 million in 2024[16]. Product and Market Development - The company has a total of 153 product offerings, including 74 proprietary products, and has established exclusive distribution agreements with 15 overseas brand partners[6][7]. - Sales of intraocular lenses reached a record high of RMB 358.6 million, representing a year-on-year growth of 13.2%[7][13]. - Revenue from proprietary products contributed RMB 429.4 million, accounting for 38.1% of total product sales, up from 31.4% in the previous year[12]. - Revenue from distributed products was RMB 697.6 million, a decrease of approximately 14.9% from RMB 819.3 million in the previous year, primarily due to macroeconomic challenges and increased competition[14]. - The company is actively expanding its product registration in new countries and regions, aiming for broader market coverage[22]. - The company plans to continue expanding its product offerings and market presence, focusing on innovation in ophthalmic medical devices and consumables[92]. Operational Efficiency - Sales and distribution expenses rose by 5.1% from RMB 232.9 million for the year ending December 31, 2024, to RMB 244.8 million for the year ending December 31, 2025, with the percentage of sales and distribution expenses to revenue increasing from 16.3% to 17.7%[35]. - Administrative expenses increased by 19.7% from RMB 145.5 million for the year ending December 31, 2024, to RMB 174.2 million for the year ending December 31, 2025, due to personnel expansion in R&D teams[36]. - The company reported a gross margin of 60%, reflecting improved operational efficiency and cost management[127]. Cash Flow and Financial Position - As of December 31, 2025, the group's cash and cash equivalents amounted to RMB 421.0 million, remaining stable compared to RMB 421.4 million as of December 31, 2024[49]. - The group generated a net cash inflow from operating activities of approximately RMB 144.2 million during the reporting period[49]. - The group's total interest-bearing bank and other borrowings were RMB 450.3 million, including short-term borrowings of RMB 135.2 million and long-term borrowings of RMB 315.1 million as of December 31, 2025[50]. - The group's debt-to-asset ratio was 29.9% as of December 31, 2025, down from 34.8% as of December 31, 2024[52]. - The company's total non-current assets increased to RMB 1,456,387 in 2025 from RMB 1,365,984 in 2024, representing an increase of approximately 6.6%[95]. Strategic Initiatives - The group plans to continue increasing R&D investment, particularly in major innovations for high-end ophthalmic medical devices, to optimize product revenue structure and enhance the contribution of self-owned products[27]. - The group aims to strengthen its market presence in both domestic and international markets, focusing on expansion in China and Europe while enhancing its global sales network[29]. - The company completed the acquisition of Teleon Holding B.V., which is anticipated to enhance its product portfolio and increase market competitiveness[128]. - A strategic partnership was formed with key opinion leaders (KOLs) in the medical field to promote new products, aiming for a 15% increase in brand awareness[126]. Regulatory and Compliance - The financial statements are prepared in accordance with International Financial Reporting Standards and are presented in RMB[79]. - The audit committee confirmed that the financial statements for the year ended December 31, 2025, comply with applicable accounting standards and regulations[70]. - The company plans to adopt new and revised International Financial Reporting Standards as they become effective, which may impact future financial reporting[85].

Gaush Meditech Ltd 高視醫療科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） （股 份 代 號：2407） 各位股東： 以電子方式發佈公司通訊之最新安排 簡介 根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）新規則第2.07A條1 以及高視醫療科技有限公 司（「本公司」）的公司章程細則，本公司將以電子通訊方式向其股東3 發佈本公司日後的公司通訊（「公司通訊」2 ）， 並僅應股東要求向其寄發印刷本形式的公司通訊。 安排 1. 可供採取行動的公司通訊4 本公司將以電子通訊方式（通過電子郵件）向股東個別地發送可供採取行動的公司通訊。如果本公司沒 有獲取股東的電子郵箱地址或其提供的電子郵箱地址無效5 ，本公司將以印刷本形式向其發送可供採取 行動的公司通訊，連同一份索取股東有效電子郵箱地址的表格，以便將來以電子通訊方式發送可供採取 行動的公司通訊。 2. 公司通訊 本公司將在本公司網站( www.gaush.com )及聯交所網站( www.hkexnews.hk )上發佈公司通訊。 本公司不會向股東發出企業通訊網站版本6 的登載通知。本公司鼓勵 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Gaush Meditech Ltd 高視醫療科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） 高视醫療科技有限公司 主席兼執行董事 高鐵塔先生 香港，2026年3月16日 於本公告日期，董事會包括主席兼執行董事高鐵塔先生，執行董事劉新偉先生、趙新禮先生、 張建軍先生及李文奇女士，非執行董事David Guowei Wang博士，以及獨立非執行董事馮昕先 生、王立新先生及陳帆城先生。 （股 份 代 號：2407） 董事會會議通告 高视医療科技有限公司（「本公司」，連同其附屬公司，統稱「本集團」）董事（「董 事」）會（「董事會」）謹此宣佈，董事會會議將於2026年3月26日（星期四）舉行， 藉以（其中包括）考慮及批准本集團截至2025年12月31日止年度的全年業績及其 發佈，並考慮建議派發末期股息（如有）。 承董事會命 ...

FF301 致：香港交易及結算所有限公司 公司名稱: 高视医疗科技有限公司 (於開曼群島註冊成立的有限責任公司) 呈交日期: 2026年3月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02407 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | USD | | 0.0001 USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 500,000,000 | USD | | 0.0001 USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 第 1 頁 共 10 頁 v 1.2.0 股份發行人及根據《上市規則》第十九B章上市的香港預託 ...

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Gaoshi Medical (02407.HK) by 39,000 shares on February 27, with a total net reduction of 93,900 shares over the last five trading days and 264,400 shares over the last 20 trading days [1] - As of now, southbound funds hold 5,587,400 shares of Gaoshi Medical, representing 3.77% of the company's total issued ordinary shares [1] Group 2 - Gaoshi Medical Technology Co., Ltd. primarily engages in the research, development, manufacturing, and sales of ophthalmic medical devices and consumables [1] - The company operates through four segments: proprietary products, distribution, technical services, and others [1] - The proprietary products segment develops and produces surgical equipment and related software, intraocular lenses, diagnostic and treatment equipment for eye diseases, and related consumables [1]

Core Viewpoint - Southbound funds have reduced their holdings in Gaoshi Medical (02407.HK) by 18,800 shares on February 26, indicating a trend of net selling over the past trading days [1] Group 1: Southbound Fund Activity - In the last 5 trading days, southbound funds have reduced their holdings for 5 days, with a total net reduction of 78,100 shares [1] - Over the past 20 trading days, southbound funds have reduced their holdings for all 20 days, with a cumulative net reduction of 226,300 shares [1] - Currently, southbound funds hold 5,626,400 shares of Gaoshi Medical, accounting for 3.8% of the company's issued ordinary shares [1] Group 2: Company Overview - Gaoshi Medical Technology Co., Ltd. is primarily engaged in the research, development, manufacturing, and sales of ophthalmic medical devices and consumables [1] - The company operates four segments: self-owned products, distribution, technical services, and other services [1] - The self-owned products segment develops and produces surgical equipment and related software, intraocular lenses, diagnostic and treatment equipment for eye diseases, and related consumables [1]

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Gaoshi Medical (02407.HK) by 7,500 shares on February 12, with a total net reduction of 60,300 shares over the past five trading days and 210,300 shares over the past twenty trading days [1] - As of now, southbound funds hold 5,645,200 shares of Gaoshi Medical, accounting for 3.81% of the company's total issued ordinary shares [1] Group 2 - Gaoshi Medical Technology Co., Ltd. primarily engages in the research, development, manufacturing, and sales of ophthalmic medical devices and consumables [1] - The company operates through four segments: self-owned products, distribution, technical services, and others [1] - The self-owned products segment develops and produces surgical equipment and related software, intraocular lenses, diagnostic and treatment equipment for eye diseases, and related consumables [1] - The distribution segment sells multifunctional diagnostic equipment, fundus diagnostic, surgical, and treatment equipment produced by other ophthalmic medical device manufacturers, along with related consumables [1] - The technical services segment provides warranty, maintenance, and after-sales services along with consumables used for these services [1] - The other segment mainly includes granting intellectual property rights and providing clinical research organization-related services [1]

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Gaoshi Medical (02407.HK) by 17,000 shares on February 11, with a total net reduction of 61,700 shares over the past five trading days and 203,800 shares over the past 20 trading days [1] - As of now, southbound funds hold 5,652,700 shares of Gaoshi Medical, representing 3.81% of the company's total issued ordinary shares [1] Group 2 - Gaoshi Medical Technology Co., Ltd. primarily engages in the research, development, manufacturing, and sales of ophthalmic medical devices and consumables [1] - The company operates through four segments: self-owned products, distribution, technical services, and others [1] - The self-owned products segment develops and produces surgical equipment and related software, intraocular lenses, diagnostic and treatment equipment for eye diseases, and related consumables [1]

Core Viewpoint - Southbound funds have reduced their holdings in Gaoshi Medical (02407.HK) significantly over recent trading days, indicating a potential shift in investor sentiment towards the company [1]. Group 1: Shareholding Changes - On February 10, 2026, southbound funds reduced their holdings by 11,600 shares, bringing the total to 5,669,700 shares, which represents a decrease of 0.20% [2]. - Over the past five trading days, there has been a cumulative net reduction of 48,500 shares, with reductions occurring on all five days [1]. - In the last twenty trading days, the total net reduction reached 197,000 shares, with reductions on all twenty days [1]. Group 2: Company Overview - Gaoshi Medical Technology Co., Ltd. is primarily engaged in the research, development, manufacturing, and sales of ophthalmic medical devices and consumables [2]. - The company operates four segments: proprietary products, distribution, technical services, and other services, including clinical research organization services [2].